NASDAQ:ACRS
Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc.'s revenue fell 58.2% in fiscal 2025 to $7.8M while operating margin fell to −975.9%. Free cash flow was −$47.2M, −603.4% of revenue, and the diluted share count rose 58.6%.Summary generated from Aclaris Therapeutics, Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$7.8M
Revenue growth−58.2%
Revenue, 5-yr CAGR+3.8%
Gross margin73.3%
Operating margin−975.9%
Net margin−829.6%
ROICn/a
Return on equity−50.2%
Debt / equityn/a
Free cash flow−$47.2M
FCF margin−603.4%
Share count change+58.6%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 7 | 30 | 31 | 19 | 8 |
| Operating income | −90 | −90 | −97 | −142 | −76 |
| Net income | −91 | −87 | −88 | −132 | −65 |
| Free cash flow | −52 | −68 | −80 | −20 | −47 |
Recent filings
- 8-KEntry into a material agreement
Aug 6, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 4Insider transaction report
Aug 4, 2026 - 4Insider transaction report
Jun 8, 2026 - 8-KResults of a shareholder vote
Jun 4, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 7, 2026 - 8-KResults of operations and financial condition
May 7, 2026